 PhaseBio Pharmaceuticals Inc NASDAQ: PHAS has entered into an exclusive licensing agreement with privately-held Alfasigma S.p.A for the commercialization of bentracimab. The agreement covers countries in the European Union and European Economic Area, and the U.K., Russia, Ukraine, and other countries within the Commonwealth of Independent States. 